Humanetics Corporation
Ronald Zenk is an accomplished executive with a robust background in finance and leadership within the pharmaceutical and healthcare industries. Since December 1988, Ronald Zenk has served as the Chief Executive Officer and a member of the Board of Directors at Humanetics Corporation, a clinical-stage specialty pharmaceutical company focused on the development of BIO 300, a drug candidate aimed at preventing radiation damage and managing inflammatory diseases. Prior to this role, Ronald Zenk held the position of Vice President Finance at Surgidyne, Inc., where innovative closed-wound drainage systems were developed. Earlier in Ronald Zenk's career, experience as a Financial Management Consultant at KPMG contributed to expertise in aligning finance organizations with business strategies. Ronald Zenk holds a Master of Business Administration in Finance from the University of Minnesota - Carlson School of Management and a Bachelor's degree in Business Administration and Management from Saint John's University.
This person is not in any teams
Humanetics Corporation
Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. Our lead candidate, BIO 300 is being developed for multiple clinical uses with a primary focus on improving treatment of solid tumor cancers. BIO 300 is being developed as an agent to both sensitize tumor cells to enhance radiation treatment efficacy and to protect normal tissues from harm. Thus, reducing common treatment related side effects such as radiation induced pneumonitis, erectile dysfunction, mucositis and xerostomia. BIO 300 is also under development for inflammatory lung diseases with an immediate focus on mitigation of pulmonary injury due to COVID-19. A recent contract from NIAID will fund a phase 2 study on BIO 300 in recovering COVID patients in an effort to stem progressive long-term lung complications, such as fibrosis. BIO 300 was licensed from the US Department of Defense, where it was originally developed to prevent injuries associated with ionizing radiation. This program is still underway with a focus on prevention of acute radiation syndrome as well as lung injury. For more information about Humanetics, please visit our corporate website at www.humaneticscorp.com.